In this article, we break down the Top 5 Healthcare Stocks to Buy With $1000 in 2026. For investors looking for the complete list, you can explore our full report on the Top 10 Healthcare Stocks to Buy With $1000 in 2026.
5. Abbott Laboratories (NYSE:ABT)
Abbott Laboratories (NYSE: ABT) moves into the top five as one of the most diversified healthcare companies in the ranking.
Instead of relying primarily on prescription medicines, Abbott Laboratories (NYSE: ABT) operates across medical devices, diagnostics, nutrition and branded generic pharmaceuticals. That broad mix gives the company exposure to everyday healthcare needs as well as some of the industry’s fastest-growing technologies.
Its recognizable products demonstrate just how diverse the business has become.
Similac gives Abbott Laboratories (NYSE: ABT) exposure to nutritional products. Alinity diagnostic systems serve laboratories and healthcare providers. FreeStyle Libre has established the company as a major competitor in continuous glucose monitoring, one of the fastest-changing markets in diabetes care.
FreeStyle Libre is particularly important to the growth thesis.
Continuous glucose monitoring allows people with diabetes to monitor glucose levels without relying exclusively on repeated traditional finger-stick testing. As these systems have become smaller, easier to use and more widely adopted, the market has expanded rapidly.
CFRA analyst Sel Hardy anticipates strong demand for FreeStyle Libre 3, reinforcing the argument that Abbott Laboratories (NYSE: ABT) can generate meaningful organic growth from medical technology even while maintaining exposure to more defensive healthcare categories.
The company is also moving more aggressively into cancer screening through its acquisition of Exact Sciences. Cancer diagnostics represent a major healthcare opportunity because earlier detection can dramatically influence treatment decisions and patient outcomes. Expanding into this market gives Abbott Laboratories (NYSE: ABT) another potential long-term growth engine while complementing its existing diagnostic capabilities.
Hardy also highlights the company’s strong balance sheet, innovative portfolio and record of consistent dividend growth. Those characteristics can make Abbott Laboratories (NYSE: ABT) particularly attractive to investors who want healthcare exposure without depending completely on speculative drug pipelines.
CFRA assigns Abbott Laboratories (NYSE: ABT) a “buy” rating and a $120 price target, compared with a July 30 closing price of $105.61. That represents approximately 14% potential upside based on the supplied figures.
The broader investment case goes beyond a single analyst target.
Healthcare is moving increasingly toward continuous monitoring, early detection and data-driven medicine. Abbott Laboratories (NYSE: ABT) participates in all three areas through glucose monitoring and diagnostics while retaining businesses in nutrition and other essential healthcare categories.
That combination helps explain why Abbott Laboratories (NYSE: ABT) deserves consideration among the best healthcare stocks to buy for long-term investors. It is not dependent on one miracle drug or one clinical trial. Instead, the company has assembled a collection of businesses that benefit from some of the healthcare industry’s most durable trends.
